Literature DB >> 18242746

A method for purifying obligate intracellular Coxiella burnetii that employs digitonin lysis of host cells.

Diane C Cockrell1, Paul A Beare, Elizabeth R Fischer, Dale Howe, Robert A Heinzen.   

Abstract

Purification of the obligate intracellular bacterium Coxiella burnetii requires physical disruption of infected cells. Here we describe a gentle and safe digitonin lysis procedure to release C. burnetii from infected cells. The purity, yield, and infectivity of digitonin-prepped organisms are comparable to that of organisms purified using cell lysis by sonication.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18242746      PMCID： PMC2276870          DOI： 10.1016/j.mimet.2007.12.015

Source DB:  PubMed          Journal:  J Microbiol Methods        ISSN： 0167-7012            Impact factor:   2.363


  22 in total

1.  Plasma membranes contain half the phospholipid and 90% of the cholesterol and sphingomyelin in cultured human fibroblasts.

Authors:  Y Lange; M H Swaisgood; B V Ramos; T L Steck
Journal:  J Biol Chem       Date:  1989-03-05       Impact factor: 5.157

2.  Separation of viable Rickettsia typhi from yolk sac and L cell host components by renografin density gradient centrifugation.

Authors:  E Weiss; J C Coolbaugh; J C Williams
Journal:  Appl Microbiol       Date:  1975-09

3.  Immunological and biological characterization of Coxiella burnetii, phases I and II, separated from host components.

Authors:  J C Williams; M G Peacock; T F McCaul
Journal:  Infect Immun       Date:  1981-05       Impact factor: 3.441

4.  Laboratory-acquired Q fever. A report of fifty cases.

Authors:  J E Johnson; P J Kadull
Journal:  Am J Med       Date:  1966-09       Impact factor: 4.965

5.  Both inducible nitric oxide synthase and NADPH oxidase contribute to the control of virulent phase I Coxiella burnetii infections.

Authors:  Robert E Brennan; Kasi Russell; Guoquan Zhang; James E Samuel
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

6.  Proteome and antigen profiling of Coxiella burnetii developmental forms.

Authors:  Sherry A Coleman; Elizabeth R Fischer; Diane C Cockrell; Daniel E Voth; Dale Howe; David J Mead; James E Samuel; Robert A Heinzen
Journal:  Infect Immun       Date:  2006-11-06       Impact factor: 3.441

7.  Rickettsia rickettsii infection of the EA.hy 926 endothelial cell line: morphological response to infection and evidence for oxidative injury.

Authors:  Marina E Eremeeva; David J Silverman
Journal:  Microbiology (Reading)       Date:  1998-08       Impact factor: 2.777

8.  A growth study of Coxiella burnetii Nine Mile Phase I and Phase II in fibroblasts.

Authors:  J D Miller; A T Curns; H A Thompson
Journal:  FEMS Immunol Med Microbiol       Date:  2004-11-01

9.  Coxiella burnetii inhabits a cholesterol-rich vacuole and influences cellular cholesterol metabolism.

Authors:  Dale Howe; Robert A Heinzen
Journal:  Cell Microbiol       Date:  2006-03       Impact factor: 3.715

10.  Purification and partial characterization of the major outer membrane protein of Chlamydia trachomatis.

Authors:  H D Caldwell; J Kromhout; J Schachter
Journal:  Infect Immun       Date:  1981-03       Impact factor: 3.441
View more
  30 in total

1.  Coxiella burnetii alters cyclic AMP-dependent protein kinase signaling during growth in macrophages.

Authors:  Laura J MacDonald; Richard C Kurten; Daniel E Voth
Journal:  Infect Immun       Date:  2012-04-02       Impact factor: 3.441

2.  Coxiella burnetii phase I and II variants replicate with similar kinetics in degradative phagolysosome-like compartments of human macrophages.

Authors:  Dale Howe; Jeffrey G Shannon; Seth Winfree; David W Dorward; Robert A Heinzen
Journal:  Infect Immun       Date:  2010-06-01       Impact factor: 3.441

3.  The Coxiella burnetii cryptic plasmid is enriched in genes encoding type IV secretion system substrates.

Authors:  Daniel E Voth; Paul A Beare; Dale Howe; Uma M Sharma; Georgios Samoilis; Diane C Cockrell; Anders Omsland; Robert A Heinzen
Journal:  J Bacteriol       Date:  2011-01-07       Impact factor: 3.490

4.  Coxiella burnetii type IVB secretion system region I genes are expressed early during the infection of host cells.

Authors:  John K Morgan; Brandon E Luedtke; Herbert A Thompson; Edward I Shaw
Journal:  FEMS Microbiol Lett       Date:  2010-08-18       Impact factor: 2.742

5.  Comparative genomics reveal extensive transposon-mediated genomic plasticity and diversity among potential effector proteins within the genus Coxiella.

Authors:  Paul A Beare; Nathan Unsworth; Masako Andoh; Daniel E Voth; Anders Omsland; Stacey D Gilk; Kelly P Williams; Bruno W Sobral; John J Kupko; Stephen F Porcella; James E Samuel; Robert A Heinzen
Journal:  Infect Immun       Date:  2008-12-01       Impact factor: 3.441

6.  Host cell-free growth of the Q fever bacterium Coxiella burnetii.

Authors:  Anders Omsland; Diane C Cockrell; Dale Howe; Elizabeth R Fischer; Kimmo Virtaneva; Daniel E Sturdevant; Stephen F Porcella; Robert A Heinzen
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-25       Impact factor: 11.205

7.  Characterization of a Coxiella burnetii ftsZ mutant generated by Himar1 transposon mutagenesis.

Authors:  Paul A Beare; Dale Howe; Diane C Cockrell; Anders Omsland; Bryan Hansen; Robert A Heinzen
Journal:  J Bacteriol       Date:  2008-12-29       Impact factor: 3.490

8.  Isolation from animal tissue and genetic transformation of Coxiella burnetii are facilitated by an improved axenic growth medium.

Authors:  Anders Omsland; Paul A Beare; Joshua Hill; Diane C Cockrell; Dale Howe; Bryan Hansen; James E Samuel; Robert A Heinzen
Journal:  Appl Environ Microbiol       Date:  2011-04-08       Impact factor: 4.792

9.  Quantitative Dextran Trafficking to the Coxiella burnetii Parasitophorous Vacuole.

Authors:  Seth Winfree; Stacey D Gilk
Journal:  Curr Protoc Microbiol       Date:  2017-08-11

10.  Sustained activation of Akt and Erk1/2 is required for Coxiella burnetii antiapoptotic activity.

Authors:  Daniel E Voth; Robert A Heinzen
Journal:  Infect Immun       Date:  2008-11-03       Impact factor: 3.441
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.